AIM ImmunoTech Inc.: AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen in multiple high-value indications - Company